在免疫媒介性肝损伤中增加多活性免疫球蛋白G,需要免疫抑制治疗
Theresa Kirchner1,2, George N Dalekos2,3, Kalliopi Zachou2,3
1Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
概括
多活性免疫球蛋白G (pIgG) 在区分自身免疫性肝炎 (AIH) 和药物诱导的自身免疫性肝炎 (DI-ALH) 与药物诱导的肝损伤 (DILI) 方面表现有前途. 这种生物标志物有助于识别需要免疫抑制治疗肝脏疾病的患者.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 区分药物诱导的肝损伤 (DILI),药物诱导的自身免疫性肝炎 (DI-ALH) 和自身免疫性肝炎 (AIH) 是临床上具有挑战性的,因为症状重叠.
- 多活性免疫球蛋白G (pIgG) 已成为AIH的潜在新生物标志物.
研究的目的:
- 评估pIgG在区分AIH,DI-ALH和DILI中的诊断准确性.
- 为了识别可能从免疫抑制疗法中受益的肝损伤患者.
主要方法:
- 对120名患有AIH,DI-ALH或DILI的患者样本的回顾性分析.
- 与对照组比较pIgG水平,包括非AIH-非DILI肝病和健康个体.
- 评估pIgG诊断准确度与传统的自身抗体 (如ANA和SMA) 相比.
主要成果:
- 与DILI和对照组相比,AIH和DI-ALH组的pIgG水平显著升高.
- 在区分这些肝病时,pIgG表现出高的诊断准确性 (AUC 0.818),与传统的自身抗体相当.
- pIgG确定了大量AIH患者对常规自身抗体负面,并在DI-ALH病例中显示出高阳性.
结论:
- pIgG作为一种有价值的生物标志物,用于识别需要免疫抑制的肝损伤.
- pIgG可以补充现有的血清学测试,提高AIH和DI-ALH的诊断准确度.
- 这一发现支持在临床实践中使用pIgG来改善患者分层和治疗决策.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
246
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
246
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
621
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
621
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
678
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
678
01:19Hypersensitivity Reactions: Immune-Complex Reactions
76
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
76
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K